Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral
Gland Pharma Ltd
-(GLAND)
XNSE:GLAND, XBOM:GLAND
Gland Pharma Ltd Q2FY24; 8% rise in Profits
Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral
Gland Pharma : Navigating the Pharmaceutical Landscape
Stock Data: TickerNSE: GLANDExchangeNSEIndustryPHARMACEUTICALS Price Performance: Last 5 Days+0.38 %YTD+8.19 %Last 12 Months-25.66%As on 15-09-2023 Company Description: Gland Pharma is a leading
Gland Pharma Ltd Q1FY24; 18% fall in Profits
Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral
Gland Pharma Limited (GLAND) Q4 FY23 Earnings Concall Transcript
Gland Pharma Limited (NSE:GLAND) Q4 FY23 Earnings Concall dated May. 18, 2023. Corporate Participants: Sumanta Bajpayee -- Vice President, Finance and Investor Relations Srinivas
Earnings Summary Of Gland Pharma Limited For Q4 FY23
Gland Pharma Limited specializes in the production of sterile injectable formulations, including vials, ampoules, pre-filled syringes, and lyophilized products. The company's focus
Earnings Summary Of Gland Pharma For Q3 FY23
Gland Pharma Limited (NSE: GLAND) is an Indian pharmaceutical company that specialises in producing high-quality, low-cost generic medications. The company has a
Gland Pharma’s Acquisition Of Cenexi & Decline In Lead Product’s Market Share
Gland Pharma Limited (NSE: GLAND) is a major player in the Indian pharmaceutical market, specialising in the production and sale of generic
Gland Pharma Limited Q3 FY23 Earnings Conference Call Insights
Key highlights from Gland Pharma Limited (GLAND) Q3 FY23 Earnings Concall Management Update: [00:06:08] GLAND said the insulin line is in the
Gland Pharma Limited (GLAND) Q3 FY23 Earnings Concall Transcript
Gland Pharma Limited (NSE:GLAND) Q3 FY23 Earnings Concall dated Jan. 23, 2023. Corporate Participants: Sumanta Bajpayee -- Vice President, Finance and Investor Relations Srinivas
Gland Pharma Limited Q3 FY23; Net Profit Down To 232 Crore
Gland Pharma Limited (NSE: GLAND) reported Revenue from Operations of ₹938.28 Crore down from ₹1,063.32 Crore year on year, a decline of
Gland Pharma Limited Q2 FY23 Earnings Conference Call Insights
https://youtu.be/4X77Cs34eLo Key highlights from Gland Pharma Limited (GLAND) Q2 FY23 Earnings Concall Management Update: [00:02:23] GLAND said it saw improvement in supplies
Infographic : Gland Pharma Ltd (NSE : GLAND) Q2 Results; Total Revenue = ₹ 1110.28 million ( UP 19.7 % QoQ)
Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral
Gland Pharma Limited (GLAND) Q2 FY23 Earnings Concall Transcript
Gland Pharma Limited (NSE:GLAND) Q2 FY23 Earnings Concall dated Oct. 26, 2022 Corporate Participants: Sumanta Bajpayee — Vice President, Corporate Finance and Investor Relations
Gland Pharma Ltd Research Tear Sheet Q1 FY 23
Gland Pharma Ltd is an Indian Pharmaceutical company. It was established in 1978, at Hyderabad, India. The founder is PVN Raju. It has
Gland Pharma Limited (GLAND) Q1 FY23 Earnings Concall Transcript
Gland Pharma Limited (NSE: GLAND) Q1 FY23 Earnings Concall dated Jul. 20, 2022 Corporate Participants: Sumanta Bajpayee -- Vice President, Corporate Finance and Investor
Gland Pharma Limited Q1 FY23 Earnings Conference Call Insights
https://youtu.be/wKPiFWdsaFY Key highlights from Gland Pharma Limited (GLAND) Q1 FY23 Earnings Concall Management Update: GLAND said it is experiencing increased attrition and
Gland Pharma Ltd. for Q1FY23 reports a 35% fall in Profits
Revenue has fell by 26% YoY to ₹8,569 millions. Core Market Revenue has decreased by 6% and Rest of the world revenue
Gland Pharma Limited (GLAND) Q1 FY23 Earnings Concall Transcript
Gland Pharma Limited (NSE:GLAND) Q1 FY23 Earnings Concall dated Jul. 20, 2022 Corporate Participants: Sumanta Bajpayee -- Vice President, Corporate Finance and Investor
Gland Pharma Ltd. (GLAND) Q4 FY22 Earnings Concall Transcript
Gland Pharma Ltd. (NSE: GLAND) Q4 FY22 Earnings Concall dated May 19, 2022 Corporate Participants: Sumanta Bajpayee -- Vice President-Finance & Investor Relations Srinivas
Gland Pharma Ltd (GLAND) Q3 FY22 Earnings Concall Transcript
Gland Pharma Limited (NSE:GLAND) Q3 FY22 Earnings Concall dated Jan. 21, 2022 Corporate participants: Sumanta Bajpayee -- Vice President- Investor Relations Srinivas